Cheer for new era with sweet music, forge ahead to build the Chinese dream. In order to boost the rapid development of tumor prevention and treatment in the Guangdong-Hong Kong-Macao Greater Bay Area, and to follow the instructions issued by the country on tumor prevention and treatment, on the afternoon of September 4, 2021, the 1st Tumor Summit Forum and Interhospital Multidisciplinary Symposium in Eastern Guangzhou (Guangzhou Royallee Cancer Center & Sun Yat-sen University Cancer Center), sponsored by Guangzhou Royallee Cancer Center (Sun Yat-sen University International Health Medical Research Center), co-organized by Sun Yat-sen University Cancer Center, the Head and Neck Cancer Branch of Guangdong Precision Medicine Application Association, the Nasopharynx Cancer Committee of Guangdong Anti-cancer Association, the Chemotherapy Committee of Guangdong Anti-cancer Association, the Pain Branch of Guangdong Medical Association and CHIA TAI TIANQING PHARMACEUTICAL GROUP, was held in the conference center of Guangzhou Royallee Cancer Center.
Centering on the “Application of tumor immunotherapy in the new era”, this conference carried out academic exchanges and in-depth academic discussions on tumor immunotherapy, tumor precision radiotherapy, tumor precision surgical treatment, tumor precision internal medicine treatment, tumor precision palliative therapy, as well as research progress of Penpulimab and the interpretation of the summary of clinical research.
Attendees included Prof. Wang Jian (Director of Tumor Palliative Medicine Center), Prof. Chen Yanfeng, Researcher Hao Wenwen, Prof. Hua Yijun, Prof. Wang Hua, Prof. Zhang Ji, Prof. Li Pengfei, together with Prof. Ma Lanying, the leader of Oncology Department of Guangzhou Royallee Cancer Center, and the head nurse Zou Benyan.
Duan Jianhua, the deputy director of Guangzhou Municipal Health Commission, Prof. Hou Jinlin, the vice chairman of Asia-Pacific Society of Hepatology, Sun Binggang, the executive vice president of Guangdong Precision Medicine Application Association, Prof. Yu Shiying, the chairman of the Cancer Rehabilitation and Palliative Care Committee of Chinese Anti-cancer Association, Prof. Huang Huiqiang, the chairman of the Lymphoma Committee of Guangdong Anti-cancer Association, Prof. Zhang Quan, the chairman of the Head and Neck Cancer Branch of the Guangdong Precision Medicine Association, together with Mr. Li Min, the chairman of Guangzhou Royallee Cancer Center and Prof. Wang Jichen, the director of Guangzhou Royallee Cancer Center congratulated the successful holding of the conference.
The forum started with a speech by Prof. Wang Jian, the executive chairman of this conference and Department of Anesthesia and Pain of Sun Yat-sen Cancer Center (Chief expert of Palliative Medicine Center of Guangzhou Royallee Cancer Center): as the cooperative unit of Sun Yat-sen Cancer Center, the leading unit of Sun Yat-sen International Health Medical Research Center and Guangzhou Eastern Caner Prevention and Treatment Institution, the backbone of Guangdong-Hong Kong-Macao Greater Bay Area tumor prevention and treatment institution, Guangzhou Royallee Cancer Center carries out multi-disciplinary and multi-level interactive exchanges in the fields of tumor clinical and fundamental research on tumor with Sun Yat-sen Cancer Center that is the top caner center in China, which is conducive to improving the overall medical technology level of Guangzhou Royallee Cancer Center, so as to explore and realize the multi-site, multi-skill and multi-expert model of cancer treatment for more patients in the Guangdong-Hong Kong-Macao Greater Bay Area.
He introduced the development of “Tumor Palliative Medicine Center”, a featured department of Guangzhou Royallee Cancer Center, to attendees. The Chinese word “shu huan” comes from the English “Palliative”. No matter it is called tumor palliative, tumor care, tumor release or tumor cure, it cannot well explain the humanistic care for tumor patients. China is a great nation that pays attention to filial piety, loyalty, emotion and life. The concept of “tumor palliative therapy” not only covers the comprehensive care and treatment of “physical, mental, social and spiritual” for cancer patients and their families, but also highlights the Chinese culture of respect and care for the sick and the weak.
Guangzhou Royallee Cancer Center, standing at the forefront of foreign exchanges in the Guangdong-Hong Kong-Macao Greater Bay Area, is the window for China’s high-end tumor treatment to the outside world, and the vanguard of export of advanced diagnosis and treatment technology along the Belt and Road. The establishment of the Palliative Medicine Center of Guangzhou Royallee Cancer Center has truly got rid of the limitations of tumor palliative therapy, and it is an advocate of a new tumor treatment in combination with comprehensive tumor therapy and palliative therapy, a guardian of the life quality of cancer patients and a practitioner of respect for patients. It actively helps tumor patients to release pain, which has won the recognition of the majority of tumor patients.
The researcher Hao Wenwen, a young scholar at Sun Yat-sen Cancer Center, introduced the R&D process, drug metabolism and drug effects of Penpulimab. She also explained the conditions and the characteristics of tumor immunotherapy in a simple way, interpreted the efficacy of Penpulimab as a new generation of tumor immunotherapy and its side effects, and introduced the latest research hotspots in anti-tumor therapy, so that everyone can know more about tumor immunotherapy.
Prof. Chen Yanfeng from the Head and Neck Department of Sun Yat-sen Cancer Center introduced the research progress and current application of Penpulimab, and explained in detail the application of immunotherapy in solid tumors and hematological tumors. He also mentioned that the combination of Penpulimab and chemo drugs or anti-vascular drugs can achieve better therapeutic effects on solid tumors and hematological tumors, providing a better option for tumor immunotherapy.
Prof. Hua Yijun from the Nasopharyngology Department of Sun Yat-sen Cancer Center, Prof. Wang Hua from the Hematology Department of Sun Yat-sen Cancer Center, Prof. Zhang Ji from the Neurosurgery Department of Sun Yat-sen Cancer Center, and Prof. Li Pengfei from Sun Yat-sen Cancer Center participated in the academic discussion, they agreed that tumor immunotherapy has become an important part for the treatment of solid tumors and hematological tumors, and has even become the first choice for first-line treatment, but its efficacy and side effects still need to be improved, and it required the joint efforts of more oncologists, pharmaceutical R&D institutions and pharmaceutical enterprises. The more new anti-tumor drugs are put into use, the more tumor patients will benefit, and the more value of oncologists will be reflected.
Finally, Prof. Ma Wang Jian made a conclusion: the wonderful lectures of the speakers won the praise of the guests and the audience. The professional attitudes and outstanding knowledge of the participating experts have benefited us a lot and provided a better reference for the future cancer treatment. It is expected that more tumor academic exchanges will be successfully carried out in the future, which will bring stronger development assistance to Guangzhou Royallee Cancer Center.
With the strong support of a number of domestic oncology experts and the interpretation of the latest achievements of tumor immunotherapy, the comprehensive ability of Guangzhou Royallee Cancer Center for individualized precision treatment has been further improved. At the same time, it strengthens the development of specialized oncology, especially tumor palliative medicine department. It aims to improve the academic status of the Center in the region and even the whole country, and take the correct development path in combination with production, education and research.
After the conference, Prof. Wang Jian and Prof. Ma Lanying accompanied Prof. Chen Yanfeng, Researcher Hao Wenwen, Prof. Hua Yijun, Prof. Wang Hua, Prof. Zhang Ji, and Prof. Li Pengfei to see around the Guangzhou Royallee Cancer Center. Its comfortable environment, complete facilities and the first-class service have left a good impression on everyone.
Move forward without forgetting the initiative aspiration, practice the mission and dedicate the sincerity. Guangzhou Royallee Cancer Center actively practices the hospital culture of patient-centered, makes continuous progress on tumor precision treatment and becomes a guardian of life.
